LONDON – Newron Pharmaceuticals Spa has resubmitted its new drug application for Xadago (safinamide) to the FDA exactly five months after receiving a refusal-to-file letter from the agency. The move comes a week after the EMA recommended the Parkinson’s disease treatment for approval, putting the company on course for EU and U.S. launches in 2015.